Download the Agenda


Speaker Information

 Xiaodong Yang
Xiaodong Yang CEO Apexigen


Main Conference Day 1

10:00 AM First Patient In Phase 1 Clinical Trial Of Immuno-oncology Therapeutic Antibody APX005M

• Assess APX005M as a stimulate for both adoptive and innate
immune responses against cancer
• Evaluation of APX005M in a Phase 1, open-label
dose-escalation study in adults with solid tumors
• Establish the MTD, pharmacokinetic profile and overall safety,
assess activation of the immune system & preliminary clinical
response to APX005M

Sponsorship Opportunities

Resource Center

Visit the Resource Center for complimentary industry related content!

IDGA

Become a Pharma IQ Member and receive our weekly newsletter!